Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease

Pathophysiology, Journal Year: 2025, Volume and Issue: 32(2), P. 13 - 13

Published: March 25, 2025

Background/Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum cholesterol levels and inflammation, both of which are dysregulated in inflammatory bowel disease (IBD). Free (FC) the various types cholesteryl ester (CE) have different functions body. However, it is not yet known whether these lipids undergo parallel changes male female patients with active IBD, nor PCSK9 correlates severity either sex. The present study measured PCSK9, FC, 15 CE species IBD patients, focusing on associations molecules sex, each other, severity. Methods: 80 (42 males 38 females) 24 controls (12 12 were by enzyme-linked immunosorbent assay. In addition, FC 53 randomly selected 16 determined direct flow injection analysis (FIA) using a high-resolution hybrid quadrupole-orbitrap mass spectrometer (FIA-FTMS). Results: Serum comparable did correlate patients. There was no discernible difference between Crohn’s (CD) those ulcerative colitis (UC). almost all decreased but related to decrease diarrhea compared normal stool consistency appears be Bile acids regulate levels, positively correlated fecal secondary bile UC CD. This association also existed could evaluated women due small sample size. Conclusions: reduction observed only males, while remained within ranges sexes. It can hypothesized that blocking may further reduce adverse effects IBD.

Language: Английский

Elevated plasma soluble lectin-like oxidised low-density lipoprotein receptor 1 as an independent prognostic biomarker in sepsis

Lipids in Health and Disease, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 13, 2025

Language: Английский

Cholesterol and Cholesterol-Lowering Medications in COVID-19—An Unresolved Matter

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10489 - 10489

Published: Sept. 29, 2024

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause disease 2019 (COVID-19), a very heterogeneous symptoms. Dyslipidaemia is prevalent in at least 20% of Europeans, and dyslipidaemia before SARS-CoV-2 infection increases the risk for COVID-19 mortality by 139%. Many reports described reduced serum cholesterol levels virus-infected patients, particular those disease. The liver major organ lipid homeostasis hepatic dysfunction appears to occur one five patients infected SARS-CoV-2. Thus, infection, severity injury may be related impaired homeostasis. These observations prompted efforts assess therapeutic opportunities cholesterol-lowering medications reduce severity. majority studies implicate statins have beneficial effects on outcome COVID-19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies also shown potential protect against This review describes relationship between systemic levels, PCSK9 are summarised. Finally, lung function, first affected SARS-CoV-2, described.

Language: Английский